Data on burden of HAE, and effectiveness of sebetralstat in children and adults unveiled at 2025 ACAAI Annual Scientific Meeting

The latest data on a new medicine for HAE, sebetralstat (brand name Ekterly), was presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting, Orlando, USA, 6-10 November 2025.

The following is a summary of some key findings:

Sebetralstat for on-demand treatment of HAE attacks in patients switching from injectable on-demand treatments

  • For 1,089 attacks treated with sebetralstat by patients in KONFIDENT-S who had switched from injectable on-demand treatments (icatibant, pdC1INH, rhC1INH), median treatment satisfaction score was 2 (very satisfied) on a 7-point Likert scale ranging from –3 (extremely dissatisfied) to 3 (extremely satisfied)
  • Overall, 84% of attacks treated with sebetralstat were rated by participants as satisfied, very satisfied, or extremely satisfied, with the vast majority being very or extremely satisfied

Sebetralstat for on-demand treatment of HAE in pediatric (2-11 years old) patients (KONFIDENT-KID)

  • Among 65 attacks treated in 26 children receiving weight-based dosing of sebetralstat in a proprietary oral disintegrating tablet (ODT) formulation as of 6 June 2025:
    • Participants treated a mean of 0.8 attacks per month
    • Caregivers or patients administered treatment in a median of 30 minutes
    • Median time to symptom relief (150 mg cohort) was 1.5 hours
  • Sebetralstat was well tolerated with no serious or treatment-related adverse events, and no reports of difficulty swallowing

Ben Palleiko, Chief Executive Officer of KalVista, said: “Hereditary angioedema affects families across generations, and the possibility of an oral on-demand option for pediatrics is profoundly meaningful—not only for patients, but for their caregivers as well. In KONFIDENT-KID, children with HAE experienced a higher frequency of attacks than previously appreciated. The availability of sebetralstat could help ensure these attacks are treated earlier and more consistently, ultimately improving care for pediatric patients and their families. The data presented at ACAAI collectively underscore the transformative potential of sebetralstat, empowering patients of all ages to treat attacks early, effectively, and without injections.”

(Source: KalVista)